{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/647732f050150f001123b38e/662270060b12320012a0c589?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Scepticaemia - helping find meaning in science","description":"<p>We meet Paul Garner (prof. emerit. and one of the founding fathers of Cochrane) and Rebecca Kuehn (Cochrane infectious diseases) for a talk about evidence-based medicine, critical appraisal and all things related to how we interpret and find the \"truth\" within research.</p><p><br></p><p><strong>Resources:</strong></p><p>1.\tIoannidis JP. Why most published research findings are false. PLoS Med. 2005;2(8):e124.</p><p>2.\tGarner P, Taylor-Robinson D, Sachdev HS. DEVTA: results from the biggest clinical trial ever. Lancet. 2013;381(9876):1439-41.</p><p>3.\tGigerenzer G. Making sense of health statistics. Bull World Health Organ. 2009;87(8):567.</p><p>4.<a href=\"https://www.badscience.net/2010/07/yeah-well-you-can-prove-anything-with-science/\" rel=\"noopener noreferrer\" target=\"_blank\">https://www.badscience.net/2010/07/yeah-well-you-can-prove-anything-with-science/</a></p><p>5.\tde Souza DK, Thomas R, Bradley J, Leyrat C, Boakye DA, Okebe J. Ivermectin treatment in humans for reducing malaria transmission. Cochrane Database Syst Rev. 2021;6(6):CD013117.</p><p>6.\tFoy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, et al. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet. 2019;393(10180):1517-26.</p><p>7.\tPopp M, Reis S, Schiesser S, Hausinger RI, Stegemann M, Metzendorf MI, et al. Ivermectin for preventing and treating COVID-19. Cochrane Database Syst Rev. 2022;6(6):CD015017.</p><p>8.\tHadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, et al. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 2015;373(13):1195-206.</p><p>9.\tDans AL, Dans LF, Lansang MAD, Silvestre MAA, Guyatt GH. Controversy and debate on dengue vaccine series-paper 1: review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs. J Clin Epidemiol. 2018;95:137-9.</p><p>10. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383-94.</p><p>11. https://bestpractice.bmj.com/info/toolkit/learn-ebm/what-is-grade/</p><p>12.Guyatt G, Vist G, Falck-Ytter Y, Kunz R, Magrini N, Schunemann H. An emerging consensus on grading recommendations? ACP J Club. 2006;144(1):A8-9.</p>","author_name":"Helse Bergen"}